Company Announcements
Director/PDMR Shareholding
Related Companies
By LSE RNS
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
2 June 2017
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Awards under the Company's Long-Term Incentive Plan
On 1 June 2017, awards over ordinary shares in Mediclinic (the "Shares") were granted to the following Directors and other persons discharging managerial responsibilities ("PDMRs") under the rules of the Company's Long-Term Incentive Plan (the "LTIP"), which was approved by shareholders in December 2015:
|
Name
|
Director/ PDMR |
Number of Shares awarded under the LTIP |
|
Danie Meintjes |
Director |
129,626 |
|
Jurgens Myburgh |
Director |
65,263 |
|
Dr Ronnie van der Merwe |
PDMR |
26,898 |
|
Gert Hattingh |
PDMR |
26,898 |
|
Dr Dirk le Roux |
PDMR |
21,211 |
|
Koert Pretorius |
PDMR |
26,691 |
|
David Hadley |
PDMR |
18,397 |
|
Dr Ole Wiesinger |
PDMR |
22,350 |
Nil consideration per share was paid for the grant of the awards, which are structured as conditional awards.
The vesting of an award is subject to the satisfaction of performance conditions set by the Remuneration Committee of the Company. The awards for PDMRs will normally vest on the later of the third anniversary of grant, other than for those PDMRs who also sit on the Board of Directors of Mediclinic International PLC whose awards will vest on the later of the fifth anniversary of grant.
The following notification made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation relates to the Company's LTIP.
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
|
a) |
Name |
Daniël Petrus Meintjes
|
||||
|
2. |
Reason for the notification
|
|||||
|
a) |
Position / status |
Chief Executive Officer of the Company
|
||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mediclinic International plc
|
||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||
|
b) |
Nature of the transaction |
Award over ordinary shares in Mediclinic International plc granted under the Company's Long Term Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume
Price |
129,626
ZAR0.00
|
||||
|
e) |
Date of the transaction |
1 June 2017
|
||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
|
a) |
Name |
Petrus Jurgens Myburgh
|
||||
|
2. |
Reason for the notification
|
|||||
|
a) |
Position / status |
Chief Financial Officer of the Company
|
||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mediclinic International plc
|
||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||
|
b) |
Nature of the transaction |
Award over ordinary shares in Mediclinic International plc granted under the Company's Long Term Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume
Price |
65,263
ZAR0.00
|
||||
|
e) |
Date of the transaction |
1 June 2017
|
||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
|
a) |
Name |
Dr Carel A van der Merwe
|
||||
|
2. |
Reason for the notification
|
|||||
|
a) |
Position / status |
Chief Clinical Officer of the Company
|
||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mediclinic International plc
|
||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||
|
b) |
Nature of the transaction |
Award over ordinary shares in Mediclinic International plc granted under the Company's Long Term Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume
Price |
26,898
ZAR0.00
|
||||
|
e) |
Date of the transaction |
1 June 2017
|
||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
|
a) |
Name |
Gert C Hattingh
|
||||
|
2. |
Reason for the notification
|
|||||
|
a) |
Position / status |
Chief Corporate Services Officer of the Company
|
||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mediclinic International plc
|
||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||
|
b) |
Nature of the transaction |
Award over ordinary shares in Mediclinic International plc granted under the Company's Long Term Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume
Price |
26,898
ZAR0.00
|
||||
|
e) |
Date of the transaction |
1 June 2017
|
||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
|
a) |
Name |
Dr Dirk Cornelius le Roux
|
||||
|
2. |
Reason for the notification
|
|||||
|
a) |
Position / status |
Chief Information Officer of the Company
|
||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mediclinic International plc
|
||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||
|
b) |
Nature of the transaction |
Award over ordinary shares in Mediclinic International plc granted under the Company's Long Term Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume
Price |
21,211
ZAR0.00
|
||||
|
e) |
Date of the transaction |
1 June 2017
|
||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
|
a) |
Name |
Koert Hendrik S Pretorius
|
||||
|
2. |
Reason for the notification
|
|||||
|
a) |
Position / status |
Chief Executive Officer - Mediclinic Southern Africa
|
||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mediclinic International plc
|
||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||
|
b) |
Nature of the transaction |
Award over ordinary shares in Mediclinic International plc granted under the Company's Long Term Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume
Price |
26,691
ZAR0.00
|
||||
|
e) |
Date of the transaction |
1 June 2017
|
||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
|
a) |
Name |
David J Hadley
|
||||
|
2. |
Reason for the notification
|
|||||
|
a) |
Position / status |
Chief Executive Officer - Mediclinic Middle East
|
||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mediclinic International plc
|
||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||
|
b) |
Nature of the transaction |
Award over ordinary shares in Mediclinic International plc granted under the Company's Long Term Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume
Price |
18,397
ZAR0.00
|
||||
|
e) |
Date of the transaction |
1 June 2017
|
||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||
|
1. |
Details of PDMR / person closely associated with them ("PCA")
|
|||||
|
a) |
Name |
Dr Thorsten Ole Wiesinger
|
||||
|
2. |
Reason for the notification
|
|||||
|
a) |
Position / status |
Chief Executive Officer - Hirslanden
|
||||
|
b) |
Initial notification / amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Mediclinic International plc
|
||||
|
b) |
LEI |
2138002S5BSBIZTD5I60
|
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares
GB00B8HX8Z88
|
||||
|
b) |
Nature of the transaction |
Award over ordinary shares in Mediclinic International plc granted under the Company's Long Term Incentive Plan
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume
Price |
22,350
ZAR0.00
|
||||
|
e) |
Date of the transaction |
1 June 2017
|
||||
|
f) |
Place of the transaction |
Johannesburg Stock Exchange |
||||
About Mediclinic International plc
Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.
Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700 inpatient beds in the United Arab Emirates.
During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.
Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Capita Company Secretarial Services Limited
Victoria Dalby
+44 (0)207 954 9600
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS
You are here: news > regulatory news
10 Lower Thames St,
London EC3R 6EN